Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation

• DOI: 10.1016/j.gore.2022.101044
• Publication Date: 2022-07-14T13:25:49Z
• Authors: Natalie Shammas; Tiffany Yang; Alireza Abidi; Malaika Amneus; Melissa Hodeib
• Keywords: Leiomyosarcoma; 0301 basic medicine; Soft tissue sarcoma; Uterine; 03 medical and health sciences; PARP inhibitor; 0302 clinical medicine; RG1-991; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Case Report; Gynecology and obstetrics; RC254-282

Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi’s may have a role in treating gynecologic malignancies with deleterious BRCA1/2 mutations. This patient is a 50-year-old female with a history of stage IB uterine leiomyosarcoma, complicated by recurrence along the vaginal cuff and metastases to the lungs. A somatic BRCA2 mutation was identified, and the patient was started on Olaparib for treatment of recurrent disease. The patient has now been disease free for two years. We recommend next generation sequencing be performed to identify functional BRCA1/2 loss in uLMS as PARPi may be a potential targeted therapy for uLMS.